Skip to content

Open Trial of Biofeedback for Respiratory Symptoms

Open Trial of Biofeedback for Respiratory Symptoms

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05973513
Enrollment
25
Registered
2023-08-03
Start date
2021-08-01
Completion date
2028-07-31
Last updated
2025-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Shortness of Breath/Dyspnea

Brief summary

Biofeedback is a therapeutic paradigm that teaches patients how to gain awareness and control over previously unrecognized sympathetic changes such as body temperature, blood pressure, and heart rate. We propose to use a six session biofeedback protocol that includes heart-rate variability (HRV) biofeedback, respiration/relaxation training, and body temperature control to treat patients with unaddressed respiratory symptoms (e.g. shortness of breath) who are under the care of pulmonologists and have not responded to traditional biomedical approaches (e.g. inhalers, pulmonary rehab, etc.).

Detailed description

Biofeedback is a therapeutic paradigm that teaches patients how to gain awareness and control over previously unrecognized sympathetic changes such as body temperature, blood pressure, and heart rate. Through a series of mind-body techniques, patients are taught to reduce sympathetic responses, leading to self-regulation over physiological responses that affect somatic sensitivity. The investigators propose to use a six session biofeedback protocol that includes heart-rate variability (HRV) biofeedback, respiration/relaxation training, and body temperature control to treat patients with unaddressed respiratory symptoms (e.g. shortness of breath) who are under the care of pulmonologists and have not responded to traditional biomedical approaches (e.g. inhalers, pulmonary rehab, etc.). The aim of the study is to determine whether patients who complete a six-session biofeedback protocol report a decrease in somatic symptoms, and improvements in self-rated mental health (depression, anxiety, quality of life) after the program and at three-months follow-up. The investigators will also study whether these improvements are also related to reduced healthcare utilization. The investigators plan to recruit up to 100 participants in the study. Participants who are screened as eligible for biofeedback for their physical ailments or psychological complaints will be asked complete a set of questionnaires before, after, and three months' post-treatment to evaluate the utility of the biofeedback treatment protocol. These questionnaires will be available online and will be completed from home. Participants who are eligible to participate but cannot complete questionnaires from home will be given the option of completing the questionnaires in the office before the first biofeedback session. Participants that cannot be immediately enrolled in the protocol due to scheduling reasons will be asked to complete the questionnaires at recruitment to serve as wait-list controls. They will complete the same consent as other participants. The investigators anticipate that questionnaires will take 30 minutes to complete, totaling about 90 minutes for participants immediately enrolled and 120 minutes for wait-list controls. Each biofeedback session will take 1 hour each. Session 1 of biofeedback will present the rationale and evidence for the treatment, teach breathing techniques, and introduce the biofeedback sensors for respiration, heart rate and temperature using the Biotrace software. The session will focus on breathing rate practice. Session 2 will introduce heart rate variability (HRV), cover breathing rhythm, and focus on the completion Resonance Frequency Assessment, an exercise to identify a participant's ideal breath rate for sustaining HRV. Session 3 will continue HRV practice using a separate software with video games, Alive. Session 4 will repeat session 3 but with more challenging practice of HRV video games. Session 5 will continue HRV practice in the first software (Biotrace) then will introduce participants to temperature control. Session 6 will repeat Session 5 but with more challenging practice for temperature control. Total time for participation will be approximately seven hours across three to six months.

Interventions

None listed

Sponsors

University of California, Los Angeles
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

1. participants must be between 18-60 2. English speaking 3. must have least one respiratory sx and have received care from a pulmonologist for this sx

Exclusion criteria

severe psychopathology (e.g., psychosis, active suicidality, moderate to severe intellectual impairment).

Design outcomes

Primary

MeasureTime frameDescription
Change in score on the SF-36After six week protocol and 3 months after six week protcolImprovement in self-rated QOL on the SF-36
Change in score on the PHQ-9After six week protocol and 3 months after six week protcolImprovement in self-rated depressive sx on the PHQ-9
Change in score on the GAD-7After six week protocol and 3 months after six week protcolImprovement in self-rated anxiety sx on the GAD-7
Change in score on the St George's Respiratory Questionnaire (SGRQ)After six week protocol and 3 months after six week protcolImprovement in self-rated respiratory sx on the SGRQ
Change in score on the PHQ-15After six week protocol and 3 months after six week protcolImprovement in self-rated physical symptoms on the PHQ-15
Change in score on the PSQIAfter six week protocol and 3 months after six week protcolImprovement in self-rated sleep quality and duration on the PSQI

Secondary

MeasureTime frameDescription
Change in healthcare utilizationAfter six week protocol and 3 months after six week protcolReduced healthcare utilization: Fewer medical visits and use of prescription and OTC meds in last month

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026